CFTR and infection: PwCF with G551D CFTR mutations showed a decrease in P. aeruginosa in sputum samples during the first year of taking VX-770/Kalydeco; however, infection is not eradicated and pathogen burden subsequently rebounded at 6 and 12 months after an initial decline [38].